

Alexa Fluor® 647 anti-mouse CD8a Antibody

Catalog# / Size	100727 / 25 µg 100724 / 100 µg
Clone	53-6.7
Regulatory Status	RUO
Other Names	T8, Lyt2, Ly-2
Isotype	Rat IgG2a, κ
Description	CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse thymus or spleen
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 647 under optimal conditions.
Concentration	0.5 mg/mL
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested IHC-F, 3D IHC - Verified SB - Reported in the literature, not verified in house
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µL volume. For immunohistochemistry on frozen tissue sections, a concentration range of 2.5 - 5.0 µg/mL is suggested. For 3D immunohistochemistry on formalin-fixed tissues, a concentration of 5.0 µg/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation. View full statement regarding label licenses
Excitation Laser	Red Laser (633 nm)
Application Notes	Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes ³ . The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a ⁺ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation ^{1,3} , <i>in vivo</i> and <i>in vitro</i> cell depletion ^{2,10,15} , inhibition of CD8 T cell proliferation ³ , blocking of cytotoxicity ^{3,4} , immunohistochemical staining ^{5,6} of acetone-fixed frozen sections and zinc-fixed paraffin-embedded

sections, and spatial biology (IBEX)^{29,30}. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes

Iterative Bleaching Extended multi-plexity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)

1. Ledbetter JA, et al. 1979. *Immunol. Rev.* 47:63. (IHC, IP)
2. Hathcock KS. 1991. *Current Protocols in Immunology*. 3.4.1. (Deplete)
3. Takahashi K, et al. 1992. *P. Natl. Acad. Sci. USA* 89:5557. (Block, IP)
4. Ledbetter JA, et al. 1981. *J. Exp. Med.* 153:1503. (Block)
5. Hata H, et al. 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Fan WY, et al. 2001. *Exp. Biol. Med.* 226:1045. (IHC)
7. Shih FF, et al. 2006. *J. Immunol.* 176:3438. (FC)
8. Kamimura D, et al. 2006. *J. Immunol.* 177:306.
9. Bouwer HGA, et al. 2006. *P. Natl. Acad. Sci. USA* 103:5102. (FC, Deplete)
10. Kao C, et al. 2005. *Int. Immunol.* 17:1607. [PubMed](#)
11. Ko SY, et al. 2005. *J. Immunol.* 175:3309. (FC) [PubMed](#)
12. Rasmussen JW, et al. 2006. *Infect. Immun.* 74:6590. [PubMed](#)
13. Lee CH, et al. 2009. *Clin. Cancer Res.* [PubMed](#)
14. Geiben-Lynn R, et al. 2008. *Blood* 112:4585. (Deplete) [PubMed](#)
15. Kingeter LM, et al. 2008. *J. Immunol.* 181:6244. [PubMed](#)
16. Guo Y, et al. 2008. *Blood* 112:480. [PubMed](#)
17. Andrews DM, et al. 2008. *J. Virol.* 82:4931. [PubMed](#)
18. Britschqui MR, et al. 2008. *J. Immunol.* 181:7681. [PubMed](#)
19. Kenna TJ, et al. 2008. *Blood* 111:2091. [PubMed](#)
20. Jordan JM, et al. 2008. *Infect. Immun.* 76:3717. [PubMed](#)
21. Todd DJ, et al. 2009. *J. Exp. Med.* 206:2151. [PubMed](#)
22. Bankoti J, et al. 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
23. Medyouf H, et al. 2010. *Blood* 115:1175. [PubMed](#)
24. Riedl P, et al. 2009. *J. Immunol.* 183:370. [PubMed](#)
25. Apte SH, et al. 2010. *J. Immunol.* 185:998. [PubMed](#)
26. Bankoti J, et al. 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
27. del Rio ML, et al. 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
28. Cui L, et al. 2015. *J Control Release.* 206:220. [PubMed](#)
29. Radtke AJ, et al. 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
30. Radtke AJ, et al. 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Minute L, et al. 2020. *J Immunother Cancer.* 8:. [PubMed](#)
2. Djokić V, et al. 2019. *Front Immunol.* 9:2891. [PubMed](#)
3. Yu X, et al. 2020. *Nat Commun.* 11:1110. [PubMed](#)
4. Parlane N, et al. 2013. *Vet Immunol Immunopathol.* 30:122. [PubMed](#)
5. Baptista AP et al. 2019. *Immunity.* 50(5):1188-1201. [PubMed](#)
6. Hu HJ, et al. 2020. *Cell Death Dis.* 1.168055556. [PubMed](#)
7. Park JJ, et al. 2021. *Nat Commun.* 12:1222. [PubMed](#)
8. Kim K, et al. 2009. *PLoS One.* 4:e7738. [PubMed](#)
9. Najjar YG, et al. 2019. *JCI Insight.* 4:. [PubMed](#)
10. Tang B, et al. 2020. *Clin Cancer Res.* 26:2216. [PubMed](#)
11. Peng Z, et al. 2021. *STAR Protocols.* 2(2):100595. [PubMed](#)
12. Dai B, et al. 2022. *Theranostics.* 12:7603. [PubMed](#)
13. Ma YV, et al. 2021. *MAbs.* 13:2003281. [PubMed](#)
14. Etxeberria I, et al. 2020. *Cancer Cell.* 36(6):613-629. [PubMed](#)
15. Schuhmann MK, et al. 2021. *J Neuroinflammation.* 18:46. [PubMed](#)
16. Seedhom M, et al. 2016. *J Immunol.* 197: 1498 - 1506. [PubMed](#)
17. Qi S et al. 2016. *eLife.* 5 pii: e14756. [PubMed](#)
18. Young R, et al. 2015. *Proc Natl Acad Sci U S A.* 112: 13447 - 13454. [PubMed](#)
19. Wang F, et al. 2019. *MAbs.* 12:1685350. [PubMed](#)
20. Liang J, et al. 2020. *Sci Adv.* 6:eabc3646. [PubMed](#)
21. Britschgi M, et al. 2008. *J Immunol.* 181:7681. [PubMed](#)
22. Kim SH, et al. 2021. *Cell Reports.* 35(2):108995. [PubMed](#)
23. Yu X, et al. 2019. *Nat Commun.* 10:574. [PubMed](#)
24. Koikawa K, et al. 2021. *Cell.* 184(18):4753-4771.e27. [PubMed](#)
25. Matryba P, et al. 2020. *J Immunol.* 1395:204. [PubMed](#)
26. Tanaka Y, et al. 2017. *J Immunol.* 199:4016. [PubMed](#)
27. von Roemeling CA, et al. 2020. *Nat Commun.* 11:1508. [PubMed](#)
28. Yu M, et al. 2021. *Molecular Cell.* 81(6):1216-1230.e9. [PubMed](#)
29. Zhang Y, et al. 2021. *Commun Biol.* 344:4. [PubMed](#)
30. Werner A, et al. 2021. *iScience.* 24:103076. [PubMed](#)
31. Rui J, et al. 2021. *Nat Commun.* 12:5074. [PubMed](#)
32. Chryplewicz A, et al. 2022. *Cancer Cell.* 40:1111. [PubMed](#)
33. Xiao M, et al. 2022. *Mol Oncol.* 16:1026. [PubMed](#)
34. Yin Y, et al. 2016. *J Biol Chem.* 291: 6923 - 6935. [PubMed](#)
35. Zhou Y, et al. 2016. *Sci Rep.* 6:28140. [PubMed](#)

36. Rasmussen J, *et al.* 2006. *Infect Immun.* 74:6590. [PubMed](#)
37. Richardson M, *et al.* 2014. *PLoS Negl Trop Dis.* 8:2825. [PubMed](#)

RRID AB_493424 (BioLegend Cat. No. 100727)
AB_389326 (BioLegend Cat. No. 100724)

Antigen Details

Structure	Ig superfamily, CD8 α chain, 34 kD
Distribution	Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function	Co-receptor for TCR
Ligand/Receptor	MHC class I molecule
Antigen References	1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press. 2. Zamoyska R. 1994. <i>Immunity</i> 1:243. 3. Ellmeier W, <i>et al.</i> 1999. <i>Annu. Rev. Immunol.</i> 17:523.
Gene ID	12525

Related Protocols

[Immunohistochemistry Protocol for Frozen Sections](#)


[Cell Surface Flow Cytometry Staining Protocol](#)

[Ce3D™ Tissue Clearing Kit](#)


Other Formats

APC anti-mouse CD8a, Biotin anti-mouse CD8a, FITC anti-mouse CD8a, PE anti-mouse CD8a, PE/Cyanine5 anti-mouse CD8a, Purified anti-mouse CD8a, PE/Cyanine7 anti-mouse CD8a, APC/Cyanine7 anti-mouse CD8a, Alexa Fluor® 488 anti-mouse CD8a, Alexa Fluor® 647 anti-mouse CD8a, Pacific Blue™ anti-mouse CD8a, Alexa Fluor® 700 anti-mouse CD8a, PerCP/Cyanine5.5 anti-mouse CD8a, PerCP anti-mouse CD8a, Brilliant Violet 421™ anti-mouse CD8a, Brilliant Violet 570™ anti-mouse CD8a, Brilliant Violet 650™ anti-mouse CD8a, Brilliant Violet 605™ anti-mouse CD8a, Ultra-LEAF™ Purified anti-mouse CD8a, Brilliant Violet 711™ anti-mouse CD8a, Brilliant Violet 785™ anti-mouse CD8a, Brilliant Violet 510™ anti-mouse CD8a, Purified anti-mouse CD8a (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD8a, PE/Dazzle™ 594 anti-mouse CD8a, APC/Fire™ 750 anti-mouse CD8a, GoInVivo™ Purified anti-mouse CD8a, TotalSeq™-A0002 anti-mouse CD8a, Spark Blue™ 550 anti-mouse CD8a, Spark NIR™ 685 anti-mouse CD8a, TotalSeq™-C0002 anti-mouse CD8a, TotalSeq™-B0002 anti-mouse CD8a, Spark YG™ 570 anti-mouse CD8a, PE/Fire™ 640 anti-mouse CD8a, PE/Fire™ 700 anti-mouse CD8a, Spark Blue™ 574 anti-mouse CD8a Antibody, Spark Violet™ 423 anti-mouse CD8a Antibody, Spark UV™ 387 anti-mouse CD8a


Product Data



C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) Alexa Fluor® 647 (filled histogram) or rat IgG2a, κ Alexa Fluor® 647 isotype control (open histogram).




C57BL/6 mouse frozen lymph node section was fixed with 4% paraformaldehyde (PFA) for 10 minutes at room temperature and blocked with 5% FBS plus 5% rat serum for 1 hour at room temperature. Then the section was stained with 5 µg/ml of B220 (clone RA3-6B2) Alexa Fluor® 594 (blue), 5 µg/ml of CD8 (clone 53-6.7) Alexa Fluor® 647 (red), and 5 µg/ml of CD4 (clone GK1.5) Alexa Fluor® 488 (green) overnight at 4°C. The image was captured by 10X objective.



Paraformaldehyde-fixed (1%), 500 µm-thick mouse spleen section was processed according to the Ce3DTM Tissue Clearing Kit protocol (cat. no. 427701). The section was costained with anti-mouse CD68 Antibody (clone FA-11) Alexa Fluor® 488 at 5 µg/mL (green), and anti-mouse CD8a Antibody (clone 53-6.7) Alexa Fluor® 647 at 5 µg/mL (magenta) and counterstained with DAPI (blue). The section was then optically cleared and mounted in a sample chamber. The image was captured with a 10X objective using Zeiss 780 confocal microscope and processed by Imaris image analysis software.

[Watch the video.](#)



Confocal image of C57BL/6 mouse lung sample acquired using the IBEX method of highly multiplexed antibody-based imaging: Ly-6G (yellow) in Cycle 2, CD31 (blue) in Cycle 3, and CD8 (red) in Cycle 4. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587